Odyssey Health, Inc. (OTCPK:ODYY) executed a non- binding letter of intent to acquire Speranza Therapeutics, Inc. on June 23, 2023. The transaction contemplates that Speranza will become a wholly owned subsidiary of Odyssey through an all-stock deal. Speranza management will remain post-closing and continue the commercialization efforts of the ST Genesis as well as other products in its pipeline.

The completion of the transaction is subject to further due diligence, financing, and other closing conditions. River Corporate Advisors, LLC acted as exclusive financial advisor to Speranza.